Imran Rashid Rangraze, Shehla Khan, Adil Farooq Wali, Godfred Menezes, Manjunatha Goud, Muhammad Jabran
{"title":"Role of Dual GIP and GLP-1 Receptor Agonist, Tirzepatide in the Management of Weight Loss; A Systematic Review","authors":"Imran Rashid Rangraze, Shehla Khan, Adil Farooq Wali, Godfred Menezes, Manjunatha Goud, Muhammad Jabran","doi":"10.2174/0115748863330434241015125302","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Tirzepatide, a dual GIP and GLP-1 receptor agonist, is a promising therapeutic option for obesity and metabolic disorders.</p><p><strong>Methods: </strong>Systematic review following PRISMA guidelines across PubMed, Embase, and Cochrane. Included RCTs and observational studies.</p><p><strong>Results: </strong>Seven phase 3 trials showed significant, dose-dependent reductions in body weight and improvements in metabolic markers. Well-tolerated, with low rates of hypoglycemia. Subgroups with higher BMI had greater benefits.</p><p><strong>Discussion: </strong>Demonstrates consistent efficacy and safety across diverse populations; personalized approaches may optimize outcomes.</p><p><strong>Conclusion: </strong>Tirzepatide is effective, safe, and durable in managing obesity and metabolic disorders; long-term studies warranted.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748863330434241015125302","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Tirzepatide, a dual GIP and GLP-1 receptor agonist, is a promising therapeutic option for obesity and metabolic disorders.
Methods: Systematic review following PRISMA guidelines across PubMed, Embase, and Cochrane. Included RCTs and observational studies.
Results: Seven phase 3 trials showed significant, dose-dependent reductions in body weight and improvements in metabolic markers. Well-tolerated, with low rates of hypoglycemia. Subgroups with higher BMI had greater benefits.
Discussion: Demonstrates consistent efficacy and safety across diverse populations; personalized approaches may optimize outcomes.
Conclusion: Tirzepatide is effective, safe, and durable in managing obesity and metabolic disorders; long-term studies warranted.
期刊介绍：
Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
